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Raf-1 phosphorylates and activates MEK-1, a kinase that activates
the extracellular signal regulated kinases (ERK). This kinase
cascade controls the proliferation and differentiation of different
cell types1,2. Here we describe a Raf-1-interacting protein, isolated
using a yeast two-hybrid screen. This protein inhibits the phos-
phorylation and activation of MEK by Raf-1 and is designated
RKIP (Raf kinase inhibitor protein). In vitro, RKIP binds to Raf-1,
MEK and ERK, but not to Ras. RKIP co-immunoprecipitates with
Raf-1 and MEK from cell lysates and colocalizes with Raf-1 when
examined by confocal microscopy. RKIP is not a substrate for Raf-
1 or MEK, but competitively disrupts the interaction between
these kinases. RKIP overexpression interferes with the activation
of MEK and ERK, induction of AP-1-dependent reporter genes
and transformation elicited by an oncogenically activated Raf-1
kinase. Downregulation of endogenous RKIP by expression of
antisense RNA or antibody microinjection induces the activation
of MEK-, ERK- and AP-1-dependent transcription. RKIP repre-
sents a new class of protein-kinase-inhibitor protein that regu-
lates the activity of the Raf/MEK/ERK module.
In metazoans the Ras/Raf-1/MEK/ERK module is a ubiquitously
expressed signalling pathway that conveys mitogenic and differen-
tiation signals from the cell membrane to the nucleus1. This kinase
cascade appears to be spatially organized in a signalling complex
that is nucleated by Ras proteins3. The regulation of the Ras/Raf-1/
MEK/ERK module is complex and may include associations with
scaffolding and regulatory proteins4. To isolate such proteins we
used the Raf-1 kinase domain, BXB5, as bait in a yeast two-hybrid
screen6. Screening 500,000 clones of a human T-cell library yielded
nine clones that speci®cally interacted with BXB. Five clones
corresponded to 14-3-3 proteins. One clone, RKIP, bound to both
kinase-active and kinase-negative BXB, but not to control baits
(Fig. 1a). Partial sequencing of the RKIP complementary DNA
predicted a protein identical to the phosphatidylethanolamine
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Figure 1 In vitro interaction of RKIP with components of the ERK pathway. a, RKIP
interacts with BXB but not with control baits in the yeast two-hybrid system. b, Binding of
recombinant BXB, full-length Raf-1, MEK-1 and ERK-2 to GST±RKIP beads. Input: 1% of
the respective proteins used in binding reactions; GST: GST-beads.
c, Co-immunoprecipitation of Raf-1, MEK and ERK with RKIP in Rat-1 cells. The RKIP
antiserum does not precipitate recombinant Raf-1, MEK-1 and ERK-2 proteins
individually. d, Colocalization of Raf-1 and RKIP in 208F ®broblasts by confocal
microscopy. Antigen competition: antisera were pre-absorbed with their cognate
antigens.
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binding proteins (PEBP) with relative molecular mass 23,000
(Mr  23K) from humans and monkeys. These proteins are
widely expressed and evolutionarily conserved, but their functions
remain obscure7.
Puri®ed recombinant RKIP was tested for binding to the com-
ponents of the Ras/Raf-1/MEK/ERK cascade. RKIP associated with
BXB, full-length Raf-1, MEK-1 and (more weakly) with ERK-2, but
not with Ras. RKIP binding was independent of Raf-1 kinase
activity, not affected by phosphatidylethanolamine, and direct, as
shown by the interaction of puri®ed proteins produced in
Escherichia coli (Fig. 1b and data not shown).
These interactions were also shown between endogenous mam-
malian proteins. An RKIP antiserum co-immunoprecipitated Raf-
1, MEK and ERK from Rat-1 cells. This was not due to cross-
reactivity, because the RKIP antiserum failed to immunoprecipitate
puri®ed Raf-1, MEK-1 or ERK-2 individually (Fig. 1c). These
interactions were also observed in reciprocal immunoprecipitations
with antisera to Raf-1, MEK or ERK (data not shown). Confocal
microscopy revealed extensive colocalization between Raf-1 and
RKIP, in both quiescent and Ras-transformed cells (Fig. 1d).
To investigate the relevance of the interaction between RKIP and
the kinases of the Raf/MEK/ERK module in mammalian cells, we
inhibited endogenous RKIP by antibody microinjection or expres-
sion of antisense RNA. As the AP-1 transcription factor is a major
target of Raf signalling8±10, we tested the in¯uence of RKIP on AP-1
activity (Fig. 2a). Microinjection of af®nity-puri®ed anti-RKIP
antibodies robustly activated a co-injected AP-1-dependent repor-
ter gene in serum-deprived Rat-1 ®broblasts (Fig. 2a). This effect
was highly speci®c, because the injection of control immunoglo-
bulin (IgG) was ineffective, anti-RKIP IgG did not affect the
expression of a cAMP-dependent reporter gene, and co-injection
of an RKIP expression vector abolished AP-1 induction by anti-RKIP
IgG. We also downregulated RKIP expression using an RKIP anti-
sense vector, pAS-C143. This vector markedly reduced RKIP levels
without affecting the expression of MEK-1 or actin (Fig. 2b). pAS-
C143 substantially induced the AP-1 reporter gene in serum-starved
NIH 3T3 cells (Fig. 2c). These data con®rm the microinjection results
and show that RKIP suppresses the Raf/MEK/ERK pathway.
Overexpression experiments further con®rmed this conclusion.
RKIP transfection diminished basal as well as BXB-induced AP-1
activity (Fig. 3a), and microinjection of an RKIP expression vector
impaired AP-1 induction by BXB (Fig. 3b). Notably, RKIP did not
interfere with AP-1 stimulation by ERK-1. Next, we tested the effects
of RKIP overexpression in transformation assays. In contrast to
transient reporter-gene assays, transformation assays accommodate
the complexity of cellular responses to the chronic deregulation of a
single signalling component. RKIP signi®cantly reduced the trans-
formation ef®ciency of BXB in three distinct assays: morphological
transformation, focus formation and anchorage-independent
growth (Fig. 3c). RKIP also decreased the total colony yield, albeit
to a lesser extent than transformation, showing that RKIP interferes
with Raf-mediated proliferation as well as transformation. In
contrast, RKIP impaired the induction of foci by v-fos or muta-
tionally activated MEK alleles only to a small extent, and failed to
inhibit v-src transformation (Fig. 3d), indicating that RKIP may
speci®cally block transformation by the Raf/MEK/ERK pathway,
primarily by inhibiting Raf.
To investigate the effects of RKIP on individual activation steps,
we reconstructed the Raf/MEK/ERK cascade in vitro using recom-
binant proteins (Fig. 4a). RKIP decreased the phosphorylation of
MEK by Raf-1, but did not inhibit ERK phosphorylation by MEK or
ELK phosphorylation by ERK. In addition, RKIP (1) failed to
inhibit MEK-DD, a constitutively active mutant of MEK11, or
MEK activated by TPA treatment of cells (Fig. 4b); (2) did not
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Figure 2 Inhibition of endogenous RKIP activates AP-1-dependent transcription.
a, Microinjection of anti-RKIP antibodies. Quiescent Rat-1 cells were microinjected with
the indicated reporter plasmids and antibodies and either left unstimulated or treated with
200 ng ml-1 TPA or 20 mg ml-1 forskolin. b, The RKIP antisense vector, pAS-C143,
downregulates expression of endogenous RKIP. NIH 3T3 cells were cotransfected with
pAS-C143 and a GFP-expressing plasmid. GFP-positive cells were isolated by FACS and
immunoblotted with the indicated antibodies. c, The activity of an AP-1 reporter gene was
measured in serum-starved or TPA-stimulated NIH 3T3 cells following cotransfection with
RKIP antisense (pAS-C143) or empty vectors.
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prevent MEK phosphorylation by MEKK-1 (Fig. 4c); and (3) did
not interfere with Raf-1 autophosphorylation or phosphorylation
of myelin basic protein (MBP) by Raf-1 (Fig. 4d). These data
indicate that RKIP is a very selective inhibitor that speci®cally
blocks activation of MEK by Raf.
In vitro, RKIP disrupted the physical interaction between Raf-1
and MEK, which is required for MEK phosphorylation12, and
behaved like a competitive inhibitor for MEK (data not shown).
Therefore, we investigated whether this mechanism also operated in
cells. The downregulation of endogenous RKIP expression by the
pAS-C143 antisense vector substantially enhanced phosphorylation
of MEK on activation-speci®c sites (Fig. 5a). Similarily, microinjec-
tion of RKIP antibodies enhanced ERK activation in NIH 3T3 cells
(Fig. 5b). In a complementary approach, RKIP was over-expressed.
Cotransfection of RKIP had only a small in¯uence on the activation
of Raf-1 by TPA, but strongly inhibited the activation of MEK in a
dose-dependent fashion (Fig. 5c). EGF produced the same results
(data not shown). RKIP overexpression also downregulated the
activation of ERKs by the v-Ras or v-Src oncogenes (Fig. 5d).
Cotransfection of increasing amounts of an RKIP expression
plasmid inhibited the BXB-induced activation of ERK in a dose-
dependent manner. In contrast, RKIP did not affect activation by
ERK by MEK-DD (Fig. 5e). These data con®rm the in vitro results
(Fig. 4), and show that RKIP regulates the ERK pathway primarily at
the Raf/MEK interface in vivo.
To test whether the association between Raf and RKIP changes
during mitogenic stimulation, we monitored the presence of RKIP
in Raf-1 immunoprecipitates prepared from Rat-1 cells at different
times after stimulation with serum (Fig. 6). The activation kinetics
of the ERK pathway closely correlated with a decrease in RKIP co-
precipitation. Furthermore, as the activity of the ERK pathway
returned to basal levels at later times following mitogenic stimula-
tion, the interaction between Raf-1 and RKIP returned to the level
seen in quiescent cells.
What could be the physiological role of an inhibitor such as
RKIP? Like the ERK pathway, RKIP is widely expressed. A quanti-
®cation of Raf-1, MEK, ERK and RKIP protein levels in the cell lines
used in this study showed a wide variation in RKIP expression
relative to the kinases. The ratio Raf-1:MEK:ERK:RKIP was
1:1.6:2.4:14 in Rat-1; 1:1.4:3.5:27 in 208F; 1:0.7:9:4.2 in NIH 3T3;
and 1:2.9:5.9:,1.9 in COS-1 cells. Thus, at least in the three
®broblast cells lines, RKIP is abundant enough to be stoichiomet-
rically relevant as an inhibitor. RKIP also colocalized with Raf-1 in
Ras-transformed cells (Fig. 1d), indicating that an appreciable
fraction of Raf-1 and its inhibitor RKIP may remain associated
even under conditions that promote Raf-1 activation. This may in
part explain the observation that only a small fraction of Raf-1 can
be activated13. We propose that RKIP could function like a rheostat
that sets the sensitivity threshold for the activation of the Raf/MEK/
ERK pathway. A quantitative analysis of the activation kinetics of
the ERK pathway showed that this cascade operates like a switch
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Figure 3 RKIP inhibits Raf-induced AP-1 activation and transformation. a, RKIP reduces
basal and BXB-induced AP-1 activity in NIH 3T3 cells cotransfected with a 3xTRE-CAT
reporter and the indicated expression plasmids. b, RKIP blocks BXB- but not ERK-induced
AP-1 activation. Rat-1 cells were co-microinjected with a 4xTRE-lacZ reporter and the
indicated expression vectors. c, RKIP inhibits Raf-dependent proliferation and
transformation. NIH 3T3 cells were transfected with BXB, alone or together with RKIP
(linked to neo). G418-resistant colonies were counted and scored for morphological
transformation. Aliquots of the same transfection were allowed to grow to con¯uency
without drug and were scored for focus formation. A BXB-transformed cell line was
infected with LXSH-RKIP retrovirus or LXSH (hygromycin resistant) and seeded in soft agar
in the presence of hygromycin. d, RKIP does not inhibit transformation by v-fos, v-src or
mutationally activated MEK11 in 208F or NIH cells. Data are expressed as reduction in
focus formation relative to cotransfection with empty vector (set to 100%).
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Figure 4 RKIP speci®cally blocks MEK phosphorylation by Raf-1. a, Effect of RKIP on the
activation steps of the Raf/MEK/ERK cascade reconstituted in vitro with puri®ed
recombinant proteins. BSA, 15 mM bovine serum albumin; Co, substrate alone; kn,
kinase-negative mutant. b, RKIP does not inhibit activated MEK. HA±MEK-DD or HA±
MEK-1 (ref. 11) expressed in COS-1 cells was immunoprecipitated with anti-HA
antibodies from serum-starved cells or TPA-treated cells, respectively, and assayed for
kinase activity. c, RKIP does not inhibit MEK phosphorylation by MEKK-1. DMEKK-1 (ref.
26) was immunoprecipitated from transiently transfected COS-1 cells and used to
phosphorylate knMEK. d, RKIP does not inhibit Raf-1 autophosphorylation or phosphor-
ylation of MBP.
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that suppresses background noise but strongly ampli®es signals
exceeding a certain threshold14. Overexpression of RKIP raises this
threshold, whereas downregulation of RKIP lowers it. As the
amplitude, kinetics and overall duration of ERK activity are
known to vary between biological responses such as cell-cycle
arrest, transformation, mitogenesis and differentiation1,15±18, RKIP
is expected to exert a profound in¯uence on these parameters. M
Methods
Plasmids and protein expression
The rat RKIP cDNA19 was cloned (1) into pcDNA3 to make p353/RKIP; (2) into pCMV5
with a triple HA-tag at the amino-terminus; and (3) into pGEX-KG to make GST±RKIP.
pAS-C143 encompasses RKIP nucleotides 1±429 cloned into pCMVori in antisense
orientation. pCMVori contains the CMV promoter, polylinker and polyadenylation
sequences from pCMV5 inserted into pUCori upstream of the polyoma virus core origin20.
6xHis-tagged MEK- and GST-fusion proteins were expressed and puri®ed as described21.
RKIP of .95% purity was prepared from GST±RKIP by thrombin cleavage22 and
subsequent FPLC separation over Superose 12.
In vitro binding assays
These contained 1±5 mg of GST-fusion protein immobilized on glutathione sepharose
beads and 0.5±5 mg puri®ed recombinant protein in PBS supplemented with 10% bovine
serum as a nonspeci®c competitor. Sf-9 cell lysates were used as a source of Raf proteins21.
After incubation for 1 h at 4 8C the samples were washed 4 times with PBS, resolved by
SDS±PAGE and blotted. The blots were developed using ECL (Amersham).
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Figure 5 RKIP regulates MEK and ERK activation in vivo. a, RKIP downregulation activates
MEK. NIH 3T3 cells were cotransfected with GFP and the RKIP antisense plasmid, pAS-
C143. GFP-positive cells were FACS sorted and immunoblotted with the indicated
antisera. b, RKIP antibody microinjection enhances ERK activation. Quiescent NIH 3T3
cells were microinjected with anti-RKIP or control IgG and stimulated with 10 ng ml-1 TPA
for 30 min. ERK activation was visualized with a monoclonal anti-phospho-ERK antibody
(Sigma) and quanti®ed densitometrically. c, RKIP inhibits MEK-1 activation. COS-1 cells
were transiently transfected with HA±MEK and increasing amounts of RKIP expression
vectors. Serum-starved cells were stimulated with 100 ng ml-1 TPA for 20 min, and the
kinase activities of Raf-1 and HA±MEK immunoprecipitates were measured. d, RKIP
inhibits stimulation of ERK by v-Ras and v-Src. COS-1 cells were transfected with the
indicated expression plasmids plus increasing amounts of RKIP. HA±ERK-2 was
immunoprecipitated and assayed with MBP. e, RKIP inhibits ERK activation by BXB, but
not by MEK-DD. COS-1 cells were transfected with the indicated expression vectors and
the kinase activity of HA±ERK immunoprecipitates was examined.
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Figure 6 During mitogenic stimulation RKIP binding to Raf-1 decreases. Serum-starved
Rat-1 cells were treated with 20% fetal calf serum for the indicated times. a, Raf-1
immunoprecipitates were immunoblotted for associated RKIP. b, Cell lysates were
examined for RKIP and ERK expression. ERK activation was monitored with a phospho-
ERK speci®c antibody.
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Immunoprecipitation
For co-precipitation experiments of endogenous proteins, 2 3 107 Rat-1 cells were lysed
by sonication in PBS, and the immunoprecipitates were washed 4 times with PBS.
Otherwise cells were lysed as described21. The antibodies used were crafVI, a peptide
antibody against the 12 carboxy-terminal amino acids of Raf-1 (ref. 21); a Raf monoclonal
antibody to the regulatory domain (Transduction Laboratories); anti-MEK H8 (Santa
Cruz); anti-RKIP raised in rabbits immunized with puri®ed GST±RKIP; anti-HA, 12CA5
monoclonal antibody; monoclonal anti-phospho-ERK (Sigma) and polyclonal anti-
phospho-MEK antibodies (New England Biolabs); and anti-GST (Pharmacia).
Kinase assays
These were done as described21. For in vitro reconstruction of the Raf/MEK/ERK cascade,
activated Raf-1 was generated by co-expressing GST±Raf-1 with v-Ras and Lck in Sf-9 cells
and collected on glutathione-sepharose beads21. Subsequent thrombin cleavage released
Raf-1, which was fully active and .90% pure. To activate MEK and ERK in vitro, 20 ng of
activated Raf-1 was incubated with 40 ng of puri®ed His/MEK-1 and 250 ng of GST±ERK-
2 in Raf kinase buffer containing 20 mM ATP for 20 min at 30 8C. To measure kinase
activities at individual steps, the respective downstream components were omitted. The
activation reactions were diluted into 50 ml Raf kinase buffer21 containing 20 mM ATP to
yield equimolar concentrations of the kinases to be assayed and incubated with increasing
amounts of puri®ed RKIP on ice for 10 min. Then, 2 mCi[32P]-g-ATP and recombinant
substrates were added and incubated for 20 min at 30 8C. As substrates, we used 200 ng
kinase negative His/MEK-1 for Raf, 1 mg kinase negative GST±ERK for MEK and 1 mg
GST±ELK (New England Biolabs) for ERK. In some assays 1 mg GST±MEKwas used as the
Raf-1 substrate with identical results.
Transfections
COS-1 cells were transfected as described23 with 2 mg of HA±ERK-2, BXB, MEK and MEK-
DD plasmids and the indicated amounts of p353/RKIP. The total amount of transfected
DNA was kept constant using the appropriate vectors as carrier DNA. NIH 3T3 and 208F
cells were transfected in 6-well plates with 1 mg of pCMV5-BXB and 3 mg of p353/RKIP
using Superfect (Qiagen). For RKIP downregulation experiments, NIH 3T3 cells were
transiently cotransfected using lipofectamine with 0.5 mg of pHACT20 and 1.5 or 3 mg
RKIP antisense expression vector (pAS-C143) or control vector (pCMVori) as indicated.
pHACTexpresses a truncated polyoma large-T construct with origin-binding activity, but
does not bind Rb or p53, and boosts the expression of pAS-C143 to high levels. In
addition, 0.1 mg of an AP1-Luc reporter was transfected for reporter-gene assays. 48 hours
after transfection, cells were serum starved for 20 h and either left untreated or treated with
TPA (200 ng ml-1) or serum for 5 h before being collected. Cells were lysed and cell extracts
were used for immunoblotting or assayed for luciferase activity. For the green ¯uorescent
protein (GFP) sorting experiments, 5 3 106 NIH 3T3 cells were electroporated with either
100 mg pCMVori, 50 mg pCMV±GFP and 50 mg pHACT, or 100 mg pASC143, 50 mg
CMV±GFP and 50 mg CMV±HAC. Two days later cells were trypsinized and sorted for
green ¯uorescent cells by preparative FACS. 100,000 GFP-positive cells were lysed in SDS-
gel sample buffer and immunoblotted.
Microinjection
Microinjection of antibodies and reporter genes was done as described24,25. The RKIP
antiserum was puri®ed over a GST±RKIP af®nity column. Cells were stained with an
activation-speci®c anti-phospho-ERK monoclonal antibody (New England Biolabs). ERK
phosphorylation was quanti®ed by densitometry. For this purpose areas with micro-
injected cells were randomly photographed, and the staining intensity of whole individual
cells was measured using the PcBAS software.
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Activation of the chromosome end-replicating enzyme telomerase
can greatly extend the lifespan of normal human cells1 and is
associated with most human cancers2. In all eukaryotes examined,
telomerase has an RNA subunit3, a conserved reverse transcriptase
subunit4 and additional proteins5,6, but little is known about the
assembly of these components. Here we show that the
Saccharomyces cerevisiae telomerase RNA7 has a 59-2,2,7-trimethyl-
guanosine (TMG) cap and a binding site for the Sm proteins, both
hallmarks of small nuclear ribonucleoprotein particles (snRNPs)
that are involved in nuclear messenger RNA splicing8,9. Immuno-
precipitation of telomerase from yeast extracts shows that Sm
proteins are assembled on the RNA and that most or all of the
telomerase activity is associated with the Sm-containing complex.
These data support a model in which telomerase RNA is transcribed
by RNA polymerase II (ref. 10) and 7-methylguanosine-capped,
